Diabetes-Induced Neuropathic Pain Model
Creative Bioarray has established the diabetic-induced neuropathic pain model induced by streptozotocin (STZ), which is the most commonly employed animal model used to study mechanisms of neuropathic pain and to evaluate potential therapies. With Creative Bioarray, you can trust that the data generated will be reliable, accurate, and directly applicable to the advancement of your drug development efforts. We invite you to explore the possibilities that our diabetic-induced neuropathic pain model can offer and to partner with us in your quest to bring new, effective treatments to patients suffering from this debilitating condition.
Diabetes is a leading cause of neuropathy, with distal symmetrical polyneuropathy (DSPN) being the most prevalent form, affecting over 90% of diabetic patients. Often, individuals seek medical attention only when pain manifests, a symptom experienced by 10% to 26% of this population. Diabetic neuropathic pain (DNP) is characterized by sensations such as tingling, burning, sharpness, shooting, and electric shock-like feelings. It is typically described as moderate to severe and tends to worsen at night, disrupting sleep. The pain can be persistent and may be accompanied by cutaneous allodynia, significantly impacting patients' quality of life, hindering daily activities, and negatively affecting mood. In diabetic neuropathy, injured sensory neurons become hyperexcitable, generating action potentials spontaneously without external stimuli and exhibiting an altered stimulus-response function. This abnormal neural activity is critical for sustaining neuropathic pain, even in patients with long-term pain conditions.
Fig. 1 Central and peripheral mechanisms contributing to neuropathic pain in diabetic neuropathy. (Feldman et al. 2019)
Our Diabetes-Induced Neuropathic Pain Model
- Available Animal
- Rat
- Mouse
- Modeling Method
STZ is administered to each animal by intraperitoneal injection to induce neuropathic pain.
- Endpoints
- Clinical observation
- Body weight
- Blood glucose
- Behavioral tests: Von Frey test, Hot plate test, etc.
- Histology analysis
- qPCR or Western blot
- Other customized endpoints
Example Data
Fig. 1 Blood glucose level of rats. (Ullah et al. 2022)
Fig. 2 Effect of the CAD extract on diabetes-induced tactile (A) and cold (B) allodynia. (Ullah et al. 2022)
In addition, we also provide other neuropathic pain models that maybe you might be interested in:
- Chemotherapy-Induced Neuropathic Pain Model
- Chronic Constriction Injury (CCI) Model
- Spared Nerve Injury (SNI) Model
- Partial Sciatic Nerve Ligation (PSL/PSNL) Model
- Spinal Nerve Ligation (SNL) Model
Quotation and Ordering
Creative Bioarray has a longstanding history of assisting our clients in navigating the complex landscape of preclinical efficacy testing to propel their groundbreaking innovations forward. With a deep bench of expertise and state-of-the-art facilities, we offer a comprehensive suite of services tailored to meet the diverse needs of our clients across various therapeutic areas. If you are interested in our services, please feel free to contact us at any time or submit an inquiry to us directly. We look forward to cooperating with you.
References
- Ullah, R., et al. Cassia artemisiodes attenuate nociceptive and diabetes-induced neuropathic pain modalities apropos antioxidant and anti-inflammatory mechanisms. Biomedicine & Pharmacotherapy, 2022, 149: 112834.
- Feldman, E.L., et al. Diabetic neuropathy. Nature reviews Disease primers, 2019, 5(1): 1-18.
- Schreiber, A.K., et al. Diabetic neuropathic pain: physiopathology and treatment. World journal of diabetes, 2015, 6(3): 432.
